Compugen Ltd
CGEN Real Time Price USDRecent trades of CGEN by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Ro Khanna House / D | Sale $15,001 - $50,000 | N/A |
| Ro Khanna House / D | Sale $1,001 - $15,000 | N/A |
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by CGEN's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
Estimated quarterly lobbying spending
CGEN Revenue by Segment or Geography
New patents grants
-
Patent Title: Triple combination antibody therapies Nov. 26, 2024
-
Patent Title: Anti-pvrig antibodies and methods of use Oct. 24, 2023
-
Patent Title: Pvrig polypeptides and methods of treatment Oct. 24, 2023
-
Patent Title: Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof Jul. 18, 2023
-
Patent Title: Anti-pvrig antibodies and methods of use Apr. 11, 2023
-
Patent Title: Triple combination antibody therapies Jan. 18, 2022
-
Patent Title: Anti-pvrig antibodies and methods of use Jan. 11, 2022
-
Patent Title: Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof Aug. 25, 2020
-
Patent Title: Pvrig polypeptides and methods of treatment Feb. 04, 2020
-
Patent Title: Anti-pvrig antibodies and methods of use Jul. 16, 2019
-
Patent Title: Anti-pvrig antibodies and methods of use Mar. 12, 2019
-
Patent Title: Anti-tigit anibodies, anti-pvrig antibodies and combinations thereof Feb. 26, 2019
-
Patent Title: Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof Nov. 13, 2018
-
Patent Title: Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics Oct. 16, 2018
-
Patent Title: Anti-pvrig antibodies and methods of use Jul. 25, 2017
-
Patent Title: C10rf32 antibodies, and uses thereof for treatment of cancer Apr. 11, 2017
-
Patent Title: Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics Jan. 31, 2017
-
Patent Title: Heparanase splice variant Aug. 30, 2016
-
Patent Title: Polypeptides and uses thereof for treatment of autoimmune disorders and infection Aug. 30, 2016
-
Patent Title: Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer Aug. 09, 2016
-
Patent Title: Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics Jun. 28, 2016
-
Patent Title: Soluble vegfr-1 variants for diagnosis of preeclampsia May. 24, 2016
-
Patent Title: Angiopoietin derived peptides Feb. 09, 2016
-
Patent Title: Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics Aug. 18, 2015
-
Patent Title: Compositions and methods for treatment of drug resistant multiple myeloma Apr. 07, 2015
-
Patent Title: Bioactive peptides and methods of using same Mar. 24, 2015
-
Patent Title: Method of treating an ischemia-reperfusion injury-related disorder by administering gpcr ligands Sep. 09, 2014
-
Patent Title: Clusterin derived peptide Nov. 05, 2013
-
Patent Title: Angiopoietin derived peptides Sep. 10, 2013
-
Patent Title: Gp96 derived peptides Aug. 20, 2013
-
Patent Title: Bioactive peptides and methods of using same Jul. 23, 2013
-
Patent Title: Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics Apr. 09, 2013
-
Patent Title: Peptide ligands for g-protein coupled receptors Jan. 08, 2013
-
Patent Title: Polynucleotides encoding polypeptides and methods using same May. 10, 2011
-
Patent Title: Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of ovarian cancer Mar. 15, 2011
-
Patent Title: Peptides which bind to g protein-coupled receptors Feb. 08, 2011
-
Patent Title: Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis Nov. 30, 2010
-
Patent Title: Hepatocyte growth factor receptor splice variants and methods of using same Jul. 20, 2010
-
Patent Title: Human thrombospondin polypeptide Jun. 29, 2010
-
Patent Title: Diagnostic markers, especially for in vivo imaging and assays and methods of use thereof Jun. 22, 2010
-
Patent Title: Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of cardiac disease May. 11, 2010
-
Patent Title: Hepatocyte growth factor receptor splice variants and methods of using same Mar. 16, 2010
-
Patent Title: Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer Feb. 23, 2010
-
Patent Title: Variants of human glycoprotein hormone alpha chain: compositions and uses thereof Feb. 02, 2010
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to CGEN
Recent picks made for CGEN stock on CNBC
ETFs with the largest estimated holdings in CGEN
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $CGEN stock a Buy, Sell, or Hold?
- What is the price target for $CGEN stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $CGEN stock?
- Who owns the most shares of $CGEN stock?
- What funds own $CGEN stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view CGEN Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.